Colchicine for the prevention of the postpericardiotomy syndrome: the COPPS trial

Abstract

Preliminary data have shown that colchicine may be considered for the prevention of the postpericardiotomy syndrome (PPS). The COlchicine for the Prevention of Post-pericardiotomy Syndrome (COPPS) study is a multicenter, double blind, placebo-controlled, randomized trial that will enroll 360 patients after cardiac surgery. The primary end point will be the PSS rate at 12 months. The study will be the first large randomized placebo-controlled trial in this area, and will provide important evidence regarding the possible benefit of colchicine for the primary prevention of the PPS.